ATE452640T1 - Mittel für erkrankungen assoziert mit knochensubstanzverlust - Google Patents

Mittel für erkrankungen assoziert mit knochensubstanzverlust

Info

Publication number
ATE452640T1
ATE452640T1 AT00977860T AT00977860T ATE452640T1 AT E452640 T1 ATE452640 T1 AT E452640T1 AT 00977860 T AT00977860 T AT 00977860T AT 00977860 T AT00977860 T AT 00977860T AT E452640 T1 ATE452640 T1 AT E452640T1
Authority
AT
Austria
Prior art keywords
diseases associated
remedies
bone loss
agonist
decrease
Prior art date
Application number
AT00977860T
Other languages
English (en)
Inventor
Tanaka Masaharu
Oida Hiroji
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Application granted granted Critical
Publication of ATE452640T1 publication Critical patent/ATE452640T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT00977860T 1999-11-24 2000-11-22 Mittel für erkrankungen assoziert mit knochensubstanzverlust ATE452640T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP33349099 1999-11-24
JP2000056534 2000-03-01
JP2000119188 2000-04-20
PCT/JP2000/008235 WO2001037877A1 (en) 1999-11-24 2000-11-22 Remedies for diseases in association with decrease in bone mass

Publications (1)

Publication Number Publication Date
ATE452640T1 true ATE452640T1 (de) 2010-01-15

Family

ID=27340604

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00977860T ATE452640T1 (de) 1999-11-24 2000-11-22 Mittel für erkrankungen assoziert mit knochensubstanzverlust

Country Status (16)

Country Link
US (1) US6891062B2 (de)
EP (1) EP1232757B1 (de)
JP (1) JP3705360B2 (de)
KR (1) KR100654653B1 (de)
CN (1) CN1262309C (de)
AT (1) ATE452640T1 (de)
AU (1) AU783939B2 (de)
CA (1) CA2391526A1 (de)
DE (1) DE60043587D1 (de)
ES (1) ES2337333T3 (de)
HU (1) HUP0203590A3 (de)
MX (1) MXPA02005173A (de)
NO (1) NO20022442L (de)
NZ (1) NZ519101A (de)
TW (1) TWI247606B (de)
WO (1) WO2001037877A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL215425B1 (pl) * 2001-07-16 2013-12-31 Ono Pharmaceutical Co Pochodna pirolidonu, srodek farmaceutyczny zawierajacy te pochodna i jej zastosowanie
JP4273407B2 (ja) * 2001-07-23 2009-06-03 小野薬品工業株式会社 Ｅｐ４アゴニストを有効成分とする骨量低下疾患の治療剤
JPWO2003041717A1 (ja) * 2001-11-12 2005-03-03 小野薬品工業株式会社 プロスタグランジン誘導体を有効成分とする局所投与用持続性フィルム状製剤
EP1878741A3 (de) * 2002-05-23 2008-02-20 Theratechnologies Inc. Antagonistische Peptide aus dem Prostaglandin-E2-Rezeptor vom Untertyp EP4
CA2485485A1 (en) * 2002-05-23 2003-12-04 Theratechnologies Inc. Antagonistic peptides of prostaglandin e2 receptor subtype ep4
WO2006075690A1 (ja) * 2005-01-14 2006-07-20 Ono Pharmaceutical Co., Ltd. 安定な医薬組成物
US7531533B2 (en) 2005-01-27 2009-05-12 Asahi Kasei Pharma Corporation 6-Membered heterocyclic compound and use thereof
EP1878429B1 (de) 2005-04-28 2011-08-03 Ono Pharmaceutical Co., Ltd. Präparat zur transdermalen absorption
US7901710B2 (en) 2005-08-04 2011-03-08 Vertical Pharmaceuticals, Inc. Nutritional supplement for use under physiologically stressful conditions
US7998500B2 (en) 2005-08-04 2011-08-16 Vertical Pharmaceuticals, Inc. Nutritional supplement for women
US8263137B2 (en) 2005-08-04 2012-09-11 Vertical Pharmaceuticals, Inc. Nutritional supplement for women
US8202546B2 (en) 2005-08-04 2012-06-19 Vertical Pharmaceuticals, Inc. Nutritional supplement for use under physiologically stressful conditions
EP1999255A2 (de) 2006-03-24 2008-12-10 The Children's Medical Center Corporation Verfahren zur modulierung des wachstums blutbildender stammzellen
EP3824885A1 (de) * 2006-10-20 2021-05-26 Children's Medical Center Corporation Verfahren zur verbesserung der geweberegeneration
US8410171B2 (en) 2006-10-26 2013-04-02 Ono Pharmaceutical Co., Ltd. Adhesive preparation
CN101686985A (zh) 2007-05-08 2010-03-31 国立大学法人浜松医科大学 含有ep4激动剂的细胞毒性t细胞的活化剂
WO2009155041A2 (en) * 2008-05-28 2009-12-23 Children's Medical Center Corporation Method to modulate hematopoietic stem cell growth
WO2010091052A2 (en) 2009-02-03 2010-08-12 Children's Medical Center Corporation Methods for enhancing hematopoietic stem/progenitor cell engraftment
WO2010096264A2 (en) 2009-02-03 2010-08-26 Children's Medical Center Corporation Methods for enhancing hematopoietic stem/progenitor cell engraftment
WO2011008756A1 (en) 2009-07-13 2011-01-20 Irix Pharmaceuticals Synthesis of prostanoids
CN104066837B (zh) 2011-12-02 2020-12-08 菲特治疗公司 增强的干细胞组合物
EP2785350B1 (de) 2011-12-02 2018-05-02 Fate Therapeutics, Inc. Verbesserte verfahren zur behandlung von ischämie
EP2875022B1 (de) 2012-07-19 2016-10-12 Cayman Chemical Company, Incorporated Difluorlactamverbindungen als ep4-rezeptorselektive agonisten zur verwendung bei der behandlung von ep4-vermittelten erkrankungen und zuständen
US10851412B2 (en) 2013-03-15 2020-12-01 Fate Therapeutics, Inc. Cell potency assay for therapeutic potential
PT2989098T (pt) 2013-03-15 2017-08-16 Cayman Chemical Co Inc Compostos de lactama como agonistas selectivos do receptor ep4 para uso no tratamento de doenças e condições mediadas por ep4
WO2014144610A1 (en) 2013-03-15 2014-09-18 Cayman Chemical Company, Inc. Lactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditions
CN105392505A (zh) 2013-07-19 2016-03-09 开曼化学股份有限公司 用于促进骨生长的方法、系统和组合物
WO2015048736A1 (en) 2013-09-30 2015-04-02 Irix Pharmaceuticals, Inc. Novel synthesis routes for prostaglandins and prostaglandin intermediates using metathesis
KR20180058758A (ko) 2015-09-22 2018-06-01 그레이버그 비젼, 인크. 안구 장애의 치료를 위한 화합물 및 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0951282T3 (da) * 1996-12-20 2008-07-14 Pfizer Forebyggelse og behandling af skeletlidelse med EP2-receptorsubtype-selektive prostaglandin E2-agonister
JPH10265454A (ja) * 1997-01-27 1998-10-06 Ono Pharmaceut Co Ltd ３，７−ジチアプロスタン酸誘導体、それらの製造方法およびそれらを有効成分として含有する薬剤
US6124314A (en) * 1997-10-10 2000-09-26 Pfizer Inc. Osteoporosis compounds
GB2330307A (en) * 1998-02-07 1999-04-21 Glaxo Group Ltd EP4 Receptor antagonists as bone resorption inhibitors
US6043275A (en) * 1998-04-16 2000-03-28 Ono Pharmaceutical Co., Ltd. 3,7-dithiaprostanoic acid derivative
TWI249520B (en) * 1998-07-15 2006-02-21 Ono Pharmaceutical Co 5-Thia-omega-substituted phenyl prostaglandin E derivatives, method for producing the same and medicines containing the same as the active ingredient
EP1114816A4 (de) 1998-09-14 2002-09-04 Ono Pharmaceutical Co $g(v)-SUBSTITUIERTE PHENYL-PROSTAGLANDIN-E-DERIVATE UND SIE ALS AKTIVEN BESTANDTEIL ENTHALTENDE MEDIKAMENTE
AU6427599A (en) * 1998-10-15 2000-05-01 Merck & Co., Inc. Methods for stimulating bone formation

Also Published As

Publication number Publication date
JP3705360B2 (ja) 2005-10-12
DE60043587D1 (de) 2010-02-04
WO2001037877A1 (en) 2001-05-31
HUP0203590A2 (hu) 2003-03-28
US6891062B2 (en) 2005-05-10
NO20022442D0 (no) 2002-05-23
CA2391526A1 (en) 2001-05-31
CN1262309C (zh) 2006-07-05
ES2337333T3 (es) 2010-04-23
CN1424918A (zh) 2003-06-18
AU1548501A (en) 2001-06-04
AU783939B2 (en) 2006-01-05
NO20022442L (no) 2002-07-24
NZ519101A (en) 2004-04-30
EP1232757A4 (de) 2004-06-16
EP1232757A1 (de) 2002-08-21
MXPA02005173A (es) 2004-02-26
US20040209848A1 (en) 2004-10-21
TWI247606B (en) 2006-01-21
KR20020059774A (ko) 2002-07-13
EP1232757B1 (de) 2009-12-23
KR100654653B1 (ko) 2006-12-07
HUP0203590A3 (en) 2006-07-28

Similar Documents

Publication Publication Date Title
DE60043587D1 (de) Mittel für erkrankungen assoziert mit knochensubstanzverlust
DE69732170D1 (de) Formulierung mit verzögerter Freisetzung enthaltend Kollagen und Glykosaminoglykan
AU2002223684A1 (en) Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity
BRPI9908182B8 (pt) composições de proteína de matriz para cura de feridas
DE69530926D1 (de) Mittel zur förderung des haarwachstums
WO2003000343A3 (en) Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
BRPI0412526A (pt) composto, uso de um composto, composição farmacêutica, formulação em aerossol farmacêutica, e, método para o tratamento de um paciente humano ou animal com uma condição anti-inflamatória e/ou alérgica
WO2003051294A3 (en) Mitocidal compositions and methods
AU2002318759A1 (en) Remedies for diseases with bone mass loss having EP4 agonists as the active ingredient
WO2001028491A3 (en) Method and composition for the treatment of dermatologic diseases
BR0114799A (pt) Compostos de ácido cianofenoxi carboxìlico e composições para liberar agentes ativos
ATE336255T1 (de) Hyaluronsäure-ester zur behandlung von normotrophischen hautnarben
DK261490D0 (da) New pharmaceutical compound
ATE417617T1 (de) Mittel zur steurung der expression von il-12
DE60035429D1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
EP1262197A3 (de) Kombinationstherapie zur Behandlung von Schlafstörungen, Schlaflosigkeit inbegriffen
ATE390124T1 (de) Behandlung von mastitis mit einer kombination aus prednisolon und cephalosporin
CA2340734A1 (en) Optically active pyridyl-4h-1,2,4-oxadiazine derivative and its use in the treatment of vascular diseases
ATE289204T1 (de) Arzneimittel zur vorbeugung / behandlung / inhibierung des fortschritts für einfache oder preproliferative retinopathie
BR0015781A (pt) Composição farmacêutica para tratamento de doenças associadas à diminuição de massa óssea
WO2002060533A3 (de) Betamimetika enthaltende arzneimittelkompositionen mit geringere n nebenwirkungen
DE69927260D1 (de) Topische pharmazeutische zusammensetzung zur behandlung von haut- oder zirkulatorischen krankheiten auf inflammatorischer, immun-, proliferativer oder degenerativer basis
SE0000303D0 (sv) Novel compounds
BR0116554A (pt) Composto, composição farmacêutica para o tratamento da angina ou hipertensão, processo, processo para o tratamento ou prevenção da angina ou hipertensão, composição do ingrediente farmaceuticamente ativo e composição farmacêutica para o tratamento ou prevenção da angina ou hipertensão
WO2001070184A3 (en) A composition containing monoterpenes for topical oral administration

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties